Dejar un mensaje
Si está interesado en nuestros productos y desea conocer más detalles, deje un mensaje aquí, le responderemos lo antes posible.
Suppression of Tumorigenicity 2 (ST2) is applied for risk stratification, disease severity evaluation, and prognosis assessment of patients with acute and chronic heart failure, as well as cardiac fibrosis and remodeling.
ST2 OEM kit utilizes a two-antibody sandwich immunoassay and is applicable to chemiluminescence platforms. Specific monoclonal antibodies target distinct epitopes on the soluble ST2 molecule to capture plasma sST2, delivering high sensitivity and exceptional specificity. Calibrated with high-purity recombinant sST2, the assay provides accurate, reliable, and stable quantitative results. Unaffected by age, BMI, or renal function, it serves as a valuable novel biomarker for cardiac fibrosis and biomechanical strain, supporting personalized risk prediction and dynamic therapeutic monitoring in heart failure management.
★Bulk reagents are available with matching raw materials.
Marca :
QYM,SURFTECHArtículo n.° :
ST2-1Pedido (MOQ) :
On requestPago :
T/TOrigen del producto :
ChinaColor :
R1 should be a colorless to pale yellow transparent liquid; R2 should be a milky white suspension.Puerto de embarque :
Hefei or other portsPlazo de entrega :
On requestPeso :
On requestST2 OEM reagent
Product Specifications
| Product Name | ST2 OEM reagent (chemiluminescence platforms) |
| Application: | It is applied for risk stratification, disease severity evaluation, and prognosis assessment of patients with acute and chronic heart failure, as well as cardiac fibrosis and remodeling. |
|
Assay Principle: |
Two-antibody sandwich immunoassay |
|
Sample Type: |
Serum / Plasma |
|
Calibrator Component: |
Recombinant ST2 |
|
Reference value |
35 ng/mL |
|
Limit of blank (LoB) |
≤0.5 ng/mL |
|
Measuring range |
1–250 ng/mL |
|
Traceability |
Critical Diagnostics |
|
Precision |
Within-run ≤5%; Between-run ≤8% |
|
Interfering Substances |
Bilirubin ＜40 mg/dL; Triglycerides ＜300 mg/dL; Biotin ≤30 ng/mL |
|
Method comparison |
Correlation coefficient (r) ＞0.975 vs Critical Diagnostics assay |
|
Hook Effect Concentration |
2500 ng/mL |
| Package Size |
on request |
| Storage/Shipping | Store sealed and protected from light at 2 °C to 8 °C |
| Shelf Life | 12 months |
Product Advantages
1.Measured sensitivity: 0.2 ng/mL, superior to industry criteria
2.Outstanding linearity ≤250 ng/mL
3.Precision CV: 1%–3%, industry-leading
4.Free of prominent high-dose hook effect ≤2500 ng/mL
5.Correlation >0.9 vs Critical Diagnostics (US)
Sensitivity Analysis Batch precision test Linear Range Validation
Application Scenarios
Suppression of Tumorigenicity 2 (ST2) is applied for risk stratification, disease severity evaluation, and prognosis assessment of patients with acute and chronic heart failure, as well as cardiac fibrosis and remodeling.
--------------占位---------------
FAQ
How well does it correlate with clinical reference platforms?
Correlation >0.9 vs Critical Diagnostics (US).
Dejar un mensaje
Escanear a WeChat :
Escanear a WhatsApp :
English
Español
IPv6 RED SOPORTADA